Macular Degeneration EURETINA 2020 Virtual Watch Time: 53 mins

touchCONGRESS Holistic approaches to patient care in nAMD

Watch this two-part activity discussing the latest developments in the clinical management of neovascular age-related macular degeneration (nAMD), filmed following the European Society of Retina Specialists (EURETINA) 2020 Virtual Congress

Part 1: Watch internationally renowned expert Prof. Anat Loewenstein review the key data on nAMD from the congress Watch Now
Part 2: Choose from leading experts who discuss what the data means for global and regional practice Select An Interview

  • Part 1: Data Review
Next Chapter
Introduction
Retinal fluid as a marker of disease activity in nAMD
Treatment discontinuation: Why it occurs and how to reduce it
Optimal dosing of anti-VEGF in nAMD: Clinical trial and real-world experience
Video Player Controls:
 
Leave Feedback
Overview

Watch Prof. Anat Loewenstein, a leading ophthalmologist, review the latest data on the clinical management of neovascular age-related macular degeneration (nAMD) from the European Society of Retina Specialists (EURETINA) 2020 Virtual Congress.

About Prof. Anat Loewenstein

Anat Loewenstein, MD, is Professor of Ophthalmology, Vice Dean of the Faculty of Medicine and Sidney Fox Chair of Ophthalmology at the Sackler Faculty of Medicine at Tel Aviv University, and Chairman of the Division of Ophthalmology at the Tel Aviv Medical Center, Tel Aviv, Israel. read more

Her main field of interest is the investigation of drug administration and toxicity to the retina, early detection of macular degeneration and home monitoring of disease. Prof. Loewenstein has led the development of novel technologies for the early detection of macular degeneration, including automated technology for the detection of retinal disease activity and augmented virtual reality to replace the operating microscope, as well as the development of home optical coherence tomography.

Prof. Loewenstein has published 400 papers in peer-reviewed journals and contributed to multiple chapters in ophthalmology textbooks. She has multiple roles in the most prominent retina societies. Today, Prof. Loewenstein serves on the International committee of the Macula Society and is currently the General Secretary of the European Society of Retina Specialists (EURETINA). In addition, she serves as the Editor in Chief of the journal Case Reports in Ophthalmology, is an associate editor of the European Journal of Ophthalmology and of Ophthalmologica.

In Israel, she serves as the president of the Israeli Ophthalmological Society and as chair of the Ministry of Health’s ethics committee. In addition, she is a member of the National Council of Surgery and Anaesthesia. Prof. Loewenstein has received multiple international awards, including the Rosenthal and Michelson Awards and the Arnall Patz Medal of the Macula Society, and the Silver Fellow Medal of the Association for Research in Vision and Ophthalmology (ARVO).

Prof. Anat Loewenstein discloses: Consultant/Advisory Board fees from Allergan, Bayer, Novartis, Notal Vision, Syneos Health

Downloads

View and download resources from this activity to support your learning or share with colleagues.

  • Part 2: Expert Interviews
Leave Feedback
Dr Carl Regillo
Watch Time: 08:54
Wills Eye Hospital and Thomas Jefferson University School of Medicine, Philadelphia, PA, USA

Find out how the latest data from the European Society of Retina Specialists (EURETINA) 2020 Virtual Congress may influence the management of patients with neovascular age-related macular degeneration.

 
Leave Feedback
Interview Questions

In this interview, Dr Carl Regillo answers the following questions:

  • How does data presented at the EURETINA 2020 Virtual Congress shape our understanding of retinal fluid measurements as markers of functional outcomes in patients with nAMD?
  • How can we integrate artificial intelligence in the management of nAMD?
  • How does recent data on novel therapeutic approaches for nAMD impact the paradigm that longer duration equals better efficacy?
  • The EURETINA 2020 Virtual Congress highlighted sharp differences between clinical trials and real-world experiences. How have these been further impacted by the COVID-19 pandemic?
  • How do you think home monitoring may encourage adherence and reduce numbers of patients lost to follow-up?
About Dr Carl Regillo

Carl D. Regillo, MD, FACS, is the Director of the Retina Service of Wills Eye Hospital and Professor of Ophthalmology at Thomas Jefferson University in Philadelphia, PA, USA read more

Dr Regillo is the founder and former Director of the Wills Eye Clinical Retina Research Unit, former Chairman of the American Academy of Ophthalmology Retina Basic and Clinical Science Course, former Chairman of the Wills Eye Institutional Review Board and prior Director of the Wills Eye Retina Fellowship.

Dr Regillo has authored over 200 publications, along with over 20 book chapters and nine major books. He has been an investigator on numerous major clinical trials developing new treatments for retinal disorders such as macular degeneration and diabetic retinopathy. He lectures worldwide and he has served on the scientific editorial boards for the American Journal of Ophthalmology, Review of Ophthalmology, Current Opinion in Ophthalmology, Yearbook of Ophthalmology, Retinal Physician and Retina Today. He is a recipient of the American Academy of Ophthalmology Achievement, Senior Achievement, Secretariat and Lifetime Achievement Awards, along with the American Society of Retina Specialists Honor, Senior Honor and Founders Awards.

Dr Carl Regillo discloses: Research Grant support from Adverum Biotechnologies, Allergan, Apellis Pharmaceuticals, Astellas Pharma, Chengdu Kanghong Pharmaceutical Group Co., Ltd., Clearside Biomedical, Genentech, Graybug Vision Inc, IVERIC bio, Kodiak Sciences, Notal Vision, Novartis, Regeneron Pharmaceuticals, REGENXBIO Inc., Roche; Consultant fees from Adverum Biotechnologies, Aldeyra Therapeutics, Allergan, Annexon Biosciences, Aviceda Therapeutics, Chengdu Kanghong Pharmaceutical Group Co., Ltd., Clearside Biomedical, Eyepoint Pharmaceuticals, Genentech, Graybug Vision Inc, IVERICbio, Kodiak Sciences, Lineage Cell Therapeutics, Merck, NGM Biopharmaceuticals, Notal Vision, Novartis, Ocugen, Inc, Roche, Stealth BioTherapeutics, Takeda.

Dr Patricia Udaondo
Watch Time: 13:11
New University and Polytechnic Hospital La Fe, Valencia, Spain

Find out how the latest data from the European Society of Retina Specialists (EURETINA) 2020 Virtual Congress may influence the management of patients with neovascular age-related macular degeneration.

 
 
Leave Feedback
Interview Questions

In this interview, Dr Patricia Udaondo answers the following questions:

  • How do data presented at the EURETINA 2020 Virtual Congress shape our understanding of retinal fluid measurements as markers of functional outcomes in patients with nAMD?
  • How can we integrate artificial intelligence in the management of nAMD?
  • How do recent data on novel therapeutic approaches for nAMD impact the paradigm that longer duration equals better efficacy?
  • The EURETINA 2020 Virtual Congress highlighted sharp differences between clinical trials and real-world experiences. How have these been further impacted by the COVID-19 pandemic?
  • How do you think home monitoring may encourage adherence and reduce numbers of patients lost to follow-up?
About Dr Patricia Udaondo

Patricia Udaondo, MD, is the cofounder, Director and Head of the Retina Division in the Aiken Ophthalmological Clinic in Valencia, Spain, and is on staff in the Medical-surgical Retina Division at the University and Polytechnic Hospital La Fe in Valencia, Spain. read more

She has previously been Professor of Ophthalmic Nursing and an Associate Professor at the University CEU Cardenal Herrera Oria. Dr Udaondo also lectures in ophthalmology at the University of Valencia. She received her Bachelor of Medicine and Surgery from the University Miguel Hernández de Elche, Spain and received the highest honours from the Hospital General Universitario de Valencia, where she specialized in ophthalmology. In 2014, she received the American Academy of Ophthalmology Achievement Award.

She has been an invited speaker at numerous national and international conferences and has been both an author and reviewer for several notable ophthalmic journals. Her main areas of interest are retinal disorders and ophthalmic surgery.

Dr Patricia Udaondo discloses: Consultant/Advisory Board fees from Alimera Sciences, Bayer, Brill Pharma; Speaker bureau fees from: Alimera Sciences, Allergan, Bayer, Brill Pharma, Novartis.

Prof. Anat Loewenstein
Watch Time: 06:32
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Find out how the latest data from the European Society of Retina Specialists (EURETINA) 2020 Virtual Congress may influence the management of patients with neovascular age-related macular degeneration (nAMD).

 
 
Leave Feedback
Interview Questions

In this interview, Prof. Anat Loewenstein answers the following questions:

  • How do data presented at the EURETINA 2020 Virtual Congress shape our understanding of retinal fluid measurements as markers of functional outcomes in patients with nAMD?
  • How can we integrate artificial intelligence in the management of nAMD?
  • How do recent data on novel therapeutic approaches for nAMD impact the paradigm that longer duration equals better efficacy?
  • The EURETINA 2020 Virtual Congress highlighted sharp differences between clinical trials and real-world experiences. How have these been further impacted by the COVID-19 pandemic?
  • How do you think home monitoring may encourage adherence and reduce numbers of patients lost to follow-up?
About Prof. Anat Loewenstein

Anat Loewenstein, MD, is Professor of Ophthalmology, Vice Dean of the Faculty of Medicine and Sidney Fox Chair of Ophthalmology at the Sackler Faculty of Medicine at Tel Aviv University, and Chairman of the Division of Ophthalmology at the Tel Aviv Medical Center, Tel Aviv, Israel. read more

Her main field of interest is the investigation of drug administration and toxicity to the retina, early detection of macular degeneration and home monitoring of disease. Prof. Loewenstein has led the development of novel technologies for the early detection of macular degeneration, including automated technology for the detection of retinal disease activity and augmented virtual reality to replace the operating microscope, as well as the development of home optical coherence tomography.

Prof. Loewenstein has published 400 papers in peer-reviewed journals and contributed to multiple chapters in ophthalmology textbooks. She has multiple roles in the most prominent retina societies. Today, Prof. Loewenstein serves on the International committee of the Macula Society and is currently the General Secretary of the European Society of Retina Specialists (EURETINA). In addition, she serves as the Editor in Chief of the journal Case Reports in Ophthalmology, is an associate editor of the European Journal of Ophthalmology and of Ophthalmologica.

In Israel, she serves as the president of the Israeli Ophthalmological Society and as chair of the Ministry of Health’s ethics committee. In addition, she is a member of the National Council of Surgery and Anaesthesia. Prof. Loewenstein has received multiple international awards, including the Rosenthal and Michelson Awards and the Arnall Patz Medal of the Macula Society, and the Silver Fellow Medal of the Association for Research in Vision and Ophthalmology (ARVO).

Prof. Anat Loewenstein discloses: Consultant/Advisory Board fees from Allergan, Bayer, Novartis, Notal Vision, Syneos Health.

Please Select A Video:
Leave Feedback
Overview & Learning Objectives
Overview

In this activity, internationally recognized experts in ophthalmology discuss the latest data on the clinical management of neovascular age-related macular degeneration (nAMD), including the use of retinal fluid as a marker of disease activity, the factors that impact treatment adherence and discontinuation, and optimal dosing strategies for anti-vascular endothelial growth factor (VEGF) therapy in nAMD, based on clinical trial and real-world experience.

Learning Objectives

After watching this activity, participants should be better able to:

  • Evaluate the use of retinal fluid as a marker of disease activity in neovascular age-related macular degeneration (nAMD)
  • Recognize the impact of factors that contribute to treatment discontinuation and evaluate ways to reduce the treatment burden in nAMD
  • Interpret results from clinical trials and real-world experience to inform on optimal dosing of anti-vascular endothelial growth factor (VEGF) therapy in nAMD
Downloads

View and download resources from this activity to support your learning or share with colleagues.

This content is intended for healthcare professionals only. Please confirm that you are a healthcare professional.

Accept Decline
Feedback Close
Feedback

Please provide feedback for this touchCONGRESS on the following
(scale 1-5, 1 strongly disagree; 5 strongly agree):

Feedback Close
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72